merger
Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
Sun Pharma and Ranbaxy merger gets US nod
February 2, 2015Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent
The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …
GSK-Novartis mega-deal signed-off by EC
January 29, 2015Research and Development, Sales and Marketing Abbott, GSK, Mylan, Novartis, acquisition, etc, merger
The European Commission has approved a GSK-Novartis M&A deal, in which GSK will purchase Novartis’ vaccines unit and Novartis will …
Pfizer buys OPKO growth hormone drug
December 16, 2014Research and Development, Sales and Marketing Pfizer, ghd, growth, hGH-CTP, hormone, merger, opko
Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
Actavis buys Allergan for $66 billion
November 18, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Canada, Valeant, merger
The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …
Allergan eyeing Actavis buyout
November 13, 2014Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Botox, Valeant, acquisition, buyout, merger
Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …
Allergan and Valeant trade blows as shareholder meeting looms
November 6, 2014Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner
Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …
AstraZeneca completes respiratory deal with Almirall
November 3, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory
AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …
Shire interim chief financial officer resigns
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Shire, james bowling, merger
Shire’s interim chief financial officer James Bowling has left the firm for water company Severn Trent following the collapse of …
AstraZeneca shores up defences against Pfizer
August 22, 2014Medical Communications, Sales and Marketing AstraZeneca, Pfizer, Read, Soriot, deal, merger
AstraZeneca has been making a series of big deals over the past three months as it looks to close the …
AbbVie agrees to buy Shire for £32bn
July 18, 2014Sales and Marketing AbbVie, Abbott, Humira, Shire, merger, new abbvie, takeover
Shire has accepted a £32 billion takeover deal from AbbVie after months of rejections and uncertainty. The firm, which is …
AbbVie makes fourth Shire offer
July 9, 2014Sales and Marketing AbbVie, Abbott, Shire, buyout, merger
The AbbVie/Shire takeover saga rumbles on, with AbbVie raising its bid for the Ireland-based biopharma specialist to $51.5 billion. The …
AbbVie spells out Shire benefits
June 26, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, merger
AbbVie has spelt out exactly why it believes that Shire should accept its $46.5 billion bid. The US firm wants …
AbbVie moves in on Shire with $46 billion bid
June 20, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Abbott, AstraZeneca, Pfizer, Shire, merger
AbbVie is looking to acquire Ireland-based speciality biopharma firm Shire in a deal that could shore up the US company’s …
Pfizer admits AstraZeneca defeat
May 27, 2014Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, Pfizer, Read, buyout, merger
Pfizer has acknowledged that it will not make an offer for AstraZeneca following the firms’ failure to agree a price …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
